ClinicalTrials.gg
Active, not recruitingNCT05184569Veri-T-001Updated Jul 6, 2026

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

A Phase 1 interventional study of Verdiperstat in Semantic Dementia, sponsored by Peter Ljubenkov, MD. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Peter Ljubenkov, MD · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Planned enrollment
31st of 66
64 · median 60
Started
2022
with 4 others
Phase 1
8 of 103
1 open now
Primary completion
2027-01
later than 15 of 44 live
Registered
73rd of 103
by date

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 31st largest by planned enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2022, is one of 8 in phase 1, reaches primary completion later than 15 of the 44 other live ones, and was the 73rd registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Approximately 64 subjects will be randomized 3:1 to active drug or placebo. Study drug will be administered orally bid (two Verdiperstat tablets bid or two placebo tablets bid (for a total daily dose of 600mg daily, following a one-week titration period of 1 tablet daily).

The study will test the effects of Verdiperstat on cerebrospinal fluid (CSF) proteins, brain magnetic resonance imaging (MRI), and cognitive (thinking, memory and language) tests in subjects with svPPA due to FTLD-TDP. This study uses placebo which looks like the experimental drug but does not have any active drug in it.

03

Conditions studied

  • Semantic Dementia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 and 85 years of age (inclusive) at the initial screening visit;
  2. Meets 2011 consensus criteria for svPPA (Gorno-Tempini et al. 2011);
  3. MRI at screening is consistent with the underlying svPPA with no large strokes or severe white matter disease (Fazekas Grade ≤2; Fazekas et al. 1987);
  4. CDR® plus NACC FTLD (Miyagawa et al. 2020) global score at screening ≤1;
  5. The following medications are allowed, but must be stable for 2 months prior to the initial screening visit:

    1. Food and Drug Administration (FDA)-approved Alzheimer's disease (AD) medications;
    2. FDA-approved psychotropic medications;
  6. Other medications (except those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to the initial screening visit;
  7. Has a reliable study partner who agrees to accompany the participant to visits, and spends at least 5 hours per week with the participant;
  8. Agrees to 2 LPs;
  9. Signed and dated written obtained from the participant and the participant's study partner in accordance with local Institutional Review Board (IRB) regulations;
  10. must agree to abstain from sex or use highly effective that includes two methods of contraception (one of which must be a barrier method) for the duration of the screening period, the RDBPC treatment period, and for 30 days after the last dose of study drug (active or placebo);
  11. Males must agree to abstain from sex with WOCBP or use an adequate method of contraception for the duration of the RDBPC treatment period and for 90 days after the last dose of study drug (active or placebo);
  12. Able to swallow pills whole without crushing or chewing.

Exclusion criteria

Exclusion Criteria:

  1. A clinical diagnosis of probable AD (McKhann et al. 2011) or previous biomarker evidence of AD biology using amyloid positron emission tomography (PET) imaging, CSF amyloid beta (Aβ)/total tau (t-tau) ratio, CSF/plasma amyloid beta isoform with 40 amino acid residues (Aβ40)/amyloid beta isoform with 42 amino acid residues (Aβ42) ratio, or plasma phosphorylated tau [phosphorylated tau at residue 181 (p-tau181) and phosphorylated tau at residue 217 (p-tau217)] assessments;
  2. A clinical diagnosis of a comorbid FTLD-associated clinical syndrome other than svPPA, including:

    1. logopenic primary progressive aphasia (lvPPA; Gorno-Tempini et al. 2011);
    2. non-fluent/agrammatic variant primary progressive aphasia (nfvPPA; Gorno-Tempini et al. 2011);

      • c. behavioral variant for frontotemporal dementia (bvFTD; Rascovsky et al. 2011). Patients who meet diagnostic criteria for svPPA (Gorno-Tempini et al. 2011) may still be included if they have a secondary diagnosis of bvFTD, so long as the PI can reasonably attribute their disinhibition, dietary changes, compulsions, and/or loss of empathy to anterior temporal lobe atrophy (Seeley et al. 2005) and MRI is consistent with right anterior atrophy (or left temporal atrophy in participants with suspected right hemispheric language dominance);

    d. progressive supranuclear palsy (PSP; Höglinger et al. 2017); e. corticobasal syndrome (CBS; Armstrong et al. 2013);

  3. Any other medical condition other than FTLD that is likely to account for cognitive or behavioral deficits (e.g., uncontrolled seizure disorder, stroke, vascular dementia, substance abuse or alcoholism, Lewy body disease);
  4. History of uncontrolled thyroid disease or evidence thereof [i.e., abnormal free thyroxine (T4) levels and thyroid stimulating hormone (TSH) > 10 milli-international units (mIU)/liter (L) at screening (confirmed by repeat)];
  5. Serious disease, or ongoing state;
  6. History of significant cardiovascular, hematologic, renal, or hepatic disease (or laboratory evidence thereof at screening);
  7. History or presence of gastrointestinal (GI) or other disease known to interfere with absorption, distribution, metabolism, or excretion of drugs, or a history of surgery known to interfere with absorption or excretion of drugs (i.e., gastric bypass);
  8. Within 1 year prior to initial screening visit or between screening and baseline (pre-dose Day 1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope;
  9. History of major psychiatric illness or untreated depression that in the opinion of the PI would pose a safety risk or interfere with the appropriate interpretation of study data;
  10. \<1,500/cubic millimeter (mm3), \<100,000/mm3, serum creatinine >1.5 x (ULN), total (TBL) >1.5 x ULN, (ALT) >1.5 x ULN, aspartate aminotransferase (AST) >1.5 x ULN, or (INR) >1.2 at screening (confirmed by repeat);
  11. Evidence of any findings on screening or baseline evaluations which, in the opinion of the PI would pose a safety risk or interfere with appropriate interpretation of study data;
  12. interval by Fridericia (QTcF) ≥ 470 milliseconds (msec) or uncontrolled arrhythmia or frequent premature ventricular contractions (PVCs; >5/minute) or Mobitz Type II second or third degree atrioventricular (AV) block or left bundle branch block or right bundle branch block with a QRS duration ≥ 150 msec or intraventricular conduction defect with a QRS duration ≥ 150 msec or evidence of acute or sub-acute myocardial infarction or ischemia or other findings at screening or baseline that, in the PI's opinion, would preclude participation in the study;
  13. Pathologic renal findings at screening as defined by the presence of either of the following criteria:

    1. Estimated (eGFR) [determined by the Modification of Diet in Renal Disease (MDRD) Study equation] \< 30 milliliter (mL)/minute/1.73 square meter (m2). The MDRD Study equation is as follows: eGFR (mL/minute/1.73 m2) = 175 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American), where Scr = serum creatinine in mg/deciliter (dL) as measured by a method calibrated to an isotope dilution mass spectrometry (IDMS) reference method;
    2. Serum creatinine ≥ 2.5 mg/dL;
  14. >7.5% at screening (confirmed by repeat);
  15. Current or recent history (within four weeks prior to initial screening visit) of a clinically significant bacterial, fungal, or mycobacterial infection;
  16. Current clinically significant viral infection, including "known" positive status for (HIV) (i.e., based on prior testing; HIV testing will not be performed as part of the screening evaluations for this trial);
  17. Major surgery within four weeks prior to initial screening visit;
  18. Blood transfusion within 4 weeks of initial screening visit;
  19. History of stem cell treatment;
  20. Any for MRI or unable to tolerate MRI at screening;
  21. Any contraindication to or unable to tolerate LP at screening, including the use of anti-coagulant medications such as warfarin. Daily administration of 81 mg aspirin will be allowed as long as the dose is stable for 30 days prior to the initial screening visit;
  22. Participants who, in the opinion of the PI, are unable or unlikely to comply with the dosing schedule or study evaluations;
  23. Prior treatment with verdiperstat;
  24. Treatment with another drug within 30 days or 5 half-lives of drug before initial screening visit, whichever is longer. Treatment with investigational drugs other than verdiperstat while on study will not be allowed;
  25. Treatment with systemic or steroid sparing systemic immunosuppressive agents within 30 days or 5 half-lives of drug before initial screening visit, whichever is longer. Treatment with systemic corticosteroids or other systemic immunosuppressive therapy while on study will not be allowed;
  26. Treatment with strong inhibitors of CYP1A2 (i.e., ciprofloxacin, enoxacin, fluvoxamine) within 30 days or 5 half-lives of drug before initial screening visit, whichever is longer. Treatment with strong inhibitors of CYP1A2 while on study will not be allowed;
  27. Known to the inactive ingredients in the study drug products (active or placebo);
  28. Known to be pregnant or lactating, or positive pregnancy test at screening or baseline (pre-dose Day 1);
  29. Cancer within 5 years of initial screening visit, except for basal cell carcinoma;
  30. History or evidence at screening of known disease-associated mutations associated with FTLD without trans-activation response deoxyribonucleic acid-binding protein of 43 kilodaltons (TDP-43) inclusions [e.g., mutations in the genes encoding chromatin-modifying protein/charged multivesicular body protein B2 (CHMPB2), microtubule-associated protein tau (MAPT), or fused in sarcoma (FUS)].
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Verdiperstat

    Verdiperstat 2 tablets twice daily (600mg total daily) by mouth for 24 weeks.

    Drug: Verdiperstat

  • Placebo comparator
    Placebo

    Placebo 2 tablets twice daily by mouth for 24 weeks.

    Drug: Verdiperstat

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Assess adverse events during 6 months administration of Verdiperstat or Placebo

    Time frame: 24 Weeks

Secondary outcomes

  1. Changes in Pharmacokinetic properties of Verdiperstat in Cerebrospinal Fluid (CSF)

    Measure steady-state cerebrospinal fluid concentrations of Verdiperstat and its metabolites

    Time frame: 24 Weeks

  2. Changes in Pharmacokinetic properties of Verdiperstat in Plasma

    Measure steady-state plasma concentrations of Verdiperstat and its metabolites

    Time frame: 24 Weeks

Other outcomes

  1. Changes in Pharmacodynamic (PD) properties of Verdiperstat in Plasma

    Measure plasma myeloperoxidase (MPO) activity

    Time frame: 24 Weeks

  2. Changes in Pharmacodynamic properties of CSF biomarkers of neurofilament light chain protein

    Measure CSF concentrations of neurofilament light chain protein (NfL) pg/ml

    Time frame: 24 Weeks

  3. Change in brain volume on brain MRI

    Measure of global and regional volumes of interest (such as whole brain and temporal lobes)

    Time frame: 24 Weeks

  4. Change in structural and functional connectivity on brain MRI

    Connectivity between brain regions measured using diffusion tensor MRI and resting state functional MRI

    Time frame: 24 Weeks

  5. Change in Clinical Dementia Rating Scale (CDR-SB)

    Measure change in dementia status using the Clinical Dementia Rating (CDR) Demential Staging Instrument plus National Alzheimer's Coordinating Center (NACC) Behavior and Language Domains (CDR plus NACC FTLD)

    Time frame: 24 Weeks

  6. Change in Executive brain function

    Measure change in executive function using the National Institutes of Health (NIH) Executive Abilities Assessment (NIH EXAMINER)

    Time frame: 24 Weeks

  7. Change in language function

    Measure change in language function using the Boston Naming Test

    Time frame: 24 Weeks

  8. Change in language semantic fluency

    Measure semantic fluency using the Delis-Kaplan Executive Function System (D-KEFS)

    Time frame: 24 Weeks

  9. Change in language naming function

    Measure language function abilities using a digitalized analysis of prompted monolog and a picture description task on a mobile application

    Time frame: 24 Weeks

  10. Change in neuropsychiatric function

    Measure using the Neuropsychiatric Inventory (NPI) questionnaire

    Time frame: 24 Weeks

07

Study locations

5 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Jan 2027, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2021
First posted
Jan 11, 2022
StartActual
Apr 14, 2022
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05184569
Lead sponsor
Peter Ljubenkov, MD
Responsible party
Peter Ljubenkov, MD (Assistant Adjunct Professor, University of California, San Francisco) — Sponsor-investigator
First posted
Jan 11, 2022
Start date
Apr 14, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Peter Ljubenkov, MD
principal investigator · University of California, San Francisco

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD3241

Start the discussion